EGFR and non-small cell lung carcinoma: By inhibiting the tyrosine kinase activity of EGFR, two tyrosine kinase inhibitors (TKIs) named gefitinib (Iressa, AstraZeneca) and erlotinib (Tarceva, Genentech) have been developed for the treatment of NSCLC.